Volume 9, Issue 4, Pages (April 2004)

Slides:



Advertisements
Similar presentations
Volume 14, Issue 3, Pages (September 2006)
Advertisements

Molecular Therapy - Methods & Clinical Development
Volume 2, Issue 3, Pages (September 2000)
Volume 22, Issue 9, Pages (September 2014)
Volume 21, Issue 2, Pages (February 2013)
The Zinc Ionophore PCI-5002 Radiosensitizes Non-small Cell Lung Cancer Cells by Enhancing Autophagic Cell Death  Kwang Woon Kim, PhD, Christina K. Speirs,
The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma  Jeff L. Hummel, Ekaterina Safroneeva,
Molecular Therapy - Nucleic Acids
Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy  Che-Hsin Lee, Chao-Liang Wu, Yun-Sheng.
Volume 10, Issue 3, Pages (September 2004)
Recombinant mumps virus as a cancer therapeutic agent
Molecular Therapy - Oncolytics
R. Sommaggio, M. Pérez-Cruz, J.L. Brokaw, R. Máñez, C. Costa 
Volume 17, Issue 12, Pages (December 2009)
Volume 13, Issue 1, Pages (January 2006)
Volume 18, Issue 9, Pages (September 2010)
Volume 10, Issue 6, Pages (December 2004)
Quantitative PET Reporter Gene Imaging with [11C]Trimethoprim
An improved mouse model for endometriosis allows noninvasive assessment of lesion implantation and development  Marylène Fortin, Ph.D., Manon Lépine,
Volume 18, Issue 11, Pages (November 2010)
Molecular Therapy - Methods & Clinical Development
Volume 22, Issue 1, Pages (January 2014)
Molecular Therapy - Oncolytics
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy
Volume 18, Issue 9, Pages (September 2010)
Volume 3, Issue 2, Pages (February 2001)
IFN-γ induces TNF family ligand protein expression in vitro and in vivo. IFN-γ induces TNF family ligand protein expression in vitro and in vivo. (A and.
Volume 22, Issue 1, Pages (January 2014)
Volume 10, Issue 5, Pages (November 2011)
Volume 8, Issue 3, Pages (September 2003)
Volume 9, Issue 6, Pages (June 2004)
Volume 21, Issue 11, Pages (November 2013)
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis
Volume 6, Issue 1, Pages (July 2002)
Volume 23, Issue 4, Pages (April 2015)
Volume 23, Issue 4, Pages (April 2015)
Volume 12, Issue 5, Pages (November 2005)
Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of niemann–pick.
Volume 16, Issue 6, Pages (June 2008)
Thomas S. Griffith, Elizabeth L. Broghammer  Molecular Therapy 
Volume 22, Issue 1, Pages (January 2014)
Volume 13, Issue 5, Pages (May 2006)
Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.
Volume 24, Issue 1, Pages (January 2016)
Elizabeth M Hadac, Elizabeth J Kelly, Stephen J Russell 
Volume 12, Issue 4, Pages (July 2015)
Volume 18, Issue 12, Pages (December 2010)
Volume 7, Issue 4, Pages (April 2003)
Molecular Therapy - Oncolytics
Volume 26, Issue 1, Pages (January 2018)
Protective Regulatory T Cell Generation in Autoimmune Diabetes by DNA Covaccination with Islet Antigens and a Selective CTLA-4 Ligand  Yelena Glinka,
Volume 3, Issue 5, Pages (May 2001)
Abhijit De, Xiaoman Zhou Lewis, Sanjiv Sam Gambhir  Molecular Therapy 
Volume 8, Issue 2, Pages (August 2003)
Volume 18, Issue 3, Pages (March 2010)
Molecular Therapy - Oncolytics
Volume 25, Issue 4, Pages (April 2017)
Volume 6, Issue 5, Pages (November 2002)
Sindbis Viral Vectors Transiently Deliver Tumor-associated Antigens to Lymph Nodes and Elicit Diversified Antitumor CD8+ T-cell Immunity  Tomer Granot,
Volume 23, Issue 3, Pages (March 2015)
Therapeutic Efficacy of G207, a Conditionally Replicating Herpes Simplex Virus Type 1 Mutant, for Gallbladder Carcinoma in Immunocompetent Hamsters  Kenji.
Volume 26, Issue 4, Pages (April 2018)
Volume 4, Issue 4, Pages (October 2001)
Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma  Chien-Kuo.
Volume 21, Issue 11, Pages (November 2013)
Volume 20, Issue 6, Pages (June 2012)
Volume 20, Issue 4, Pages (April 2012)
Volume 18, Issue 2, Pages (February 2010)
Volume 15, Issue 2, Pages (February 2007)
Volume 12, Issue 5, Pages (November 2005)
Presentation transcript:

Volume 9, Issue 4, Pages 540-547 (April 2004) Quantitative Assessment of Human Endometriotic Tissue Maintenance and Regression in a Noninvasive Mouse Model of Endometriosis  Marylène Fortin, Manon Lépine, Yannick Merlen, Isabelle Thibeault, Claudine Rancourt, Diane Gosselin, Patrice Hugo, Ann-Muriel Steff  Molecular Therapy  Volume 9, Issue 4, Pages 540-547 (April 2004) DOI: 10.1016/j.ymthe.2003.12.012 Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 1 Noninvasive in vivo imaging of fluorescent endometrial implants allows dynamic monitoring of lesion development. Endometrial fragments were incubated with AdGFP viral particles for 20 h. After washings, five fragments were injected subcutaneously into ovariectomized nude mice supplemented (N = 8) or not (N = 8) with E2-releasing pellets. Each mouse was repeatedly imaged in triplicate, and images acquired at days 4, 6, 8, 12, 14, 16, 19, 23, 27, and 29 posttransplantation are shown for one mouse in each group. Molecular Therapy 2004 9, 540-547DOI: (10.1016/j.ymthe.2003.12.012) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 2 Quantification of endometriotic-like lesion size in ovariectomized mice supplemented or not with E2. Ovariectomized nude mice having received or not an E2 pellet (N = 8 for each group) were periodically imaged in triplicate, and endometriotic-like lesion size (number of pixels) was quantified by image analysis. Each symbol represents the mean of three measures for each animal at each time point. Bars indicate the mean surface of endometriotic implants for each group. Comparison of lesion size in estradiol-supplemented versus nonsupplemented animals was performed by a nonparametric Mann–Whitney test. A significant difference in size of lesions is observed between the two groups starting from day 12 (P ≤ 0.05 at days 12, 27, and 29; P ≤ 0.005 at days 13, 14, 16, 19, 21, and 23). These results are representative of six independent experiments. Molecular Therapy 2004 9, 540-547DOI: (10.1016/j.ymthe.2003.12.012) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 3 Kaplan–Meier analysis of endometriotic-like lesion regression in mice lacking estradiol supplementation. Ovariectomized nude mice having received or not an E2 pellet (N = 8 for each group) were periodically imaged in triplicate, and endometriotic-like lesion size (number of pixels) was quantified with image analysis software. The time at which each mouse had a lesion with (A) a 75% or (B) a 50% reduction in its initial size was used to generate survival curves (Kaplan–Meier analysis). A significant difference was observed between E2-supplemented and nonsupplemented groups (log rank test, P = 0.0001 and P = 0.0002 for A and B, respectively). Molecular Therapy 2004 9, 540-547DOI: (10.1016/j.ymthe.2003.12.012) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 4 Ganciclovir treatment induces cell death in an endometrial cell line expressing the thymidine kinase gene. HEC-1A cells were infected with either AdGFP or AdTK viral particles at an m.o.i. of 1. The proportions of cells expressing either GFP or TK 1 day prior to GCV treatment were 76 and 24%, respectively. Treatment with increasing doses of ganciclovir (GCV) was initiated 5 days postinfection and was pursued for 7 days. At the end of GCV treatment, cells were harvested and cell death was assessed by propidium iodide (PI) staining and flow cytometry. The percentage of apoptotic cells for each GCV dose is shown. Molecular Therapy 2004 9, 540-547DOI: (10.1016/j.ymthe.2003.12.012) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 5 Ganciclovir treatment induces a significant regression of endometrial implants expressing the TK gene in nude mice. Endometrial fragments were incubated with AdGFP (m.o.i. 500) and AdTK (m.o.i. 25) viral particles for 20 h. After washings, five fragments were injected subcutaneously into 16 ovariectomized nude mice supplemented with E2-releasing pellets. Eight mice received an ip injection of GCV (50 mg/kg/day) on each weekday for a 2-week period, starting 4 days after tissue transplantation. Mice in the control group (N = 8) received PBS injections. Each mouse was imaged in triplicate at days 1, 4, 6, 8, 11, 13, 15, 18, 20, and 22 posttransplantation, and lesion size was quantified. (A) Each symbol represents the mean of three measures for each animal at each time point. Bars indicate the mean surface of endometriotic implants for each group. Comparison of lesion size (in pixels) in treated versus untreated animals was performed by a nonparametric Mann–Whitney test. A significant difference between GCV- and PBS-treated groups was observed (P ≤ 0.05 at days 8, 15, 18, 20, and 22; P ≤ 0.005 at days 11 and 13). (B and C) The time at which each mouse had a lesion with (B) a 75% or (C) a 50% reduction from its initial size was used to generate survival curves (Kaplan–Meier analysis). A significant difference was observed between GCV- and PBS-treated groups (log rank test, P = 0.004 and P = 0.006 for B and C, respectively). These results are representative of two independent experiments. Molecular Therapy 2004 9, 540-547DOI: (10.1016/j.ymthe.2003.12.012) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions